A Randomized Trial of Standard vs. Hypofractionated Accelerated Radiotherapy for Progression in Limited-Stage Small Cell Lung Cancer
Key facts
- Where
- London, CanadaSee the site
- Phase
- Phase 2/3
Where in Canada
- London Health Sciences Centre - Verspeeten Family Cancer CentreLondon, CanadaNo longer taking part
Questions to ask the study team
- How often do I need to come in, and for how long each time?
- Are travel costs paid?
- Can I keep my own doctor?
- What happens if I want to stop?
Trial details
- Who runs it
- London Health Sciences Centre Research Institute OR Lawson Research Institute of St. Joseph's
- Trial code
- NCT07920549
- Record updated
- 5 November 2026
- Original description
This study aims to determine whether an abbreviated course of thoracic radiotherapy, delivered in five fractions over one week between chemotherapy cycles, improves progression-free survival compared with standard radiotherapy delivered concurrently with chemotherapy in patients with newly diagnosed limited-stage small cell lung cancer (LS-SCLC).Read full original descriptionShow less
A Randomized Trial of Standard vs. Hypofractionated Accelerated Radiotherapy for Progression in Limited-Stage Small Cell Lung Cancer (SHARP-SCLC)
This study aims to determine whether an abbreviated course of thoracic radiotherapy, delivered in five fractions over one week between chemotherapy cycles, improves progression-free survival compared with standard radiotherapy delivered concurrently with chemotherapy in patients with newly diagnosed limited-stage small cell lung cancer (LS-SCLC).
Inclusion: New diagnosis of Limited-stage small cell lung cancer (LS-SCLC), eligible for curative intent concurrent chemoradiotherapy; -- Planned for immunotherapy and prophylactic cranial irradiation is allowed and encouraged; Eastern Cooperative Oncology Group (ECOG) performance status 0-2; Age 18 years or older; Life expectancy > 3 months; Willingness and ability to provide informed consent.
Exclusion: Prior thoracic radiation therapy (RT) which, in the opinion of the treating radiation oncologist, precludes the delivery of further thoracic RT; If there has been prior thoracic RT, a composite of all RT plans must be created, and the dose constraints herein must still be met; An allowance for 10% repair is permitted if at least 12 months have passed between the prior RT and the trial protocol specified RT; Patients who have started systemic treatment for LS-SCLC but are unable to start radiation with cycle 3 or earlier (delaying scheduled chemotherapy without clinical indication) is not permitted; Serious medical comorbidities which, in the opinion of the treating radiation oncologist, preclude the delivery of RT; -- This includes interstitial lung disease; Pregnant or lactating women; Inability to attend the full course of RT or planed follow-up visits.